Loading…
Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the likelihood of a positive sentinel lymph node and the risk of metastasis for patients with invasive cutaneous melanoma; TissueCypher, a risk stratification spatialomics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, and low-grade dysplasia BE; AdvanceAD-Tx, a non-invasive GEP test which is designed to guide systemic treatment selection for patients aged 12 years and older with moderateto-severe AD; DecisionDx-SCC, a GEP test for cutaneous squamous cell carcinoma; and MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions. It also provides DecisionDx-UM, a risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma. The company offers its products to dermatology and gastroenterology markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $344M | $11M | $-24M | $28M | -5.1% | 3.7% | -232.4% |
| 2024 | $332M | $38M | $18M | $37M | 4.0% | 51.1% | -131.7% |
| 2023 | $220M | $-45M | $-57M | $-19M | -14.7% | 60.4% | -14.4% |
| 2022 | $137M | $-58M | $-67M | $-47M | -16.8% | - | - |
| 2021 | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 137.04 | 219.79 | 332.07 | 344.23 |
| Operating Revenue | - | 137.04 | 219.79 | 332.07 | 344.23 |
| Cost Of Revenue | - | 32.01 | 44.98 | 60.20 | 71.03 |
| Gross Profit | - | 105.03 | 174.81 | 271.86 | 273.20 |
| Operating Expense | - | 196.17 | 242.78 | 263.19 | 316.01 |
| Research And Development | - | 44.90 | 53.62 | 52.04 | 51.85 |
| Selling General And Administration | - | 143 | 180.15 | 200.05 | 229.32 |
| Total Expenses | - | 228.18 | 287.76 | 323.40 | 387.04 |
| Operating Income | - | -91.14 | -67.98 | 8.67 | -42.81 |
| Total Operating Income As Reported | - | -72.86 | -67.98 | 8.67 | -42.81 |
| EBITDA | - | -58.34 | -45.02 | 38.14 | 11.34 |
| Normalized EBITDA | - | -76.63 | -45.02 | 37.58 | 9.88 |
| EBIT | - | -68.89 | -57.35 | 22.14 | -29.43 |
| Interest Income | - | 3.97 | 10.62 | 12.92 | 11.77 |
| Interest Expense | - | 0.02 | 0.01 | 0.58 | 0.09 |
| Net Interest Income | - | 3.95 | 10.61 | 12.34 | 11.69 |
| Other Non Operating Income Expenses | - | - | - | 0.56 | 0.14 |
| Other Income Expense | - | 18.29 | - | 0.56 | 1.61 |
| Interest Income Non Operating | - | 3.97 | 10.62 | 12.92 | 11.77 |
| Interest Expense Non Operating | - | 0.02 | 0.01 | 0.58 | 0.09 |
| Net Non Operating Interest Income Expense | - | 3.95 | 10.61 | 12.34 | 11.69 |
| Pretax Income | - | -68.90 | -57.36 | 21.56 | -29.51 |
| Tax Provision | - | -1.77 | 0.10 | 3.32 | -5.36 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0.47 | 0 | 0.09 | 0.27 |
| Net Income Continuous Operations | - | -67.14 | -57.47 | 18.24 | -24.16 |
| Net Income From Continuing And Discontinued Operation | - | -67.14 | -57.47 | 18.24 | -24.16 |
| Net Income From Continuing Operation Net Minority Interest | - | -67.14 | -57.47 | 18.24 | -24.16 |
| Net Income | - | -67.14 | -57.47 | 18.24 | -24.16 |
| Net Income Common Stockholders | - | -67.14 | -57.47 | 18.24 | -24.16 |
| Net Income Including Noncontrolling Interests | - | -67.14 | -57.47 | 18.24 | -24.16 |
| Normalized Income | - | -84.96 | -57.47 | 17.78 | -25.36 |
| Diluted NI Availto Com Stockholders | - | -67.14 | -57.47 | 18.24 | -24.16 |
| Basic Average Shares | - | 26.05 | 26.80 | 27.78 | 28.99 |
| Diluted Average Shares | - | 26.05 | 26.80 | 29.26 | 28.99 |
| Reconciled Depreciation | - | 10.54 | 12.33 | 16 | 40.77 |
| Reconciled Cost Of Revenue | - | 29.73 | 41.66 | 55.31 | 65.10 |
| Total Unusual Items | - | 18.29 | 0 | 0.56 | 1.47 |
| Total Unusual Items Excluding Goodwill | - | 18.29 | 0 | 0.56 | 1.47 |
| Special Income Charges | 0 | 18.29 | 0 | 0 | - |
| Restructuring And Mergern Acquisition | 0 | -18.29 | 0 | 0 | - |
| Gain On Sale Of Security | - | - | - | 0.56 | 1.47 |
| Depreciation Amortization Depletion Income Statement | - | 8.27 | 9.01 | 11.11 | 34.84 |
| Depreciation And Amortization In Income Statement | - | 8.27 | 9.01 | 11.11 | 34.84 |
| General And Administrative Expense | - | 56.40 | 66.50 | 76.58 | 91.21 |
| Other Gand A | - | 56.40 | 66.50 | 76.58 | 91.21 |
| Selling And Marketing Expense | - | 86.61 | 113.66 | 123.47 | 138.12 |
| Amortization | - | 8.27 | 9.01 | 11.11 | 34.84 |
| Amortization Of Intangibles Income Statement | - | 8.27 | 9.01 | 11.11 | 34.84 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Castle Biosciences, Inc.this co. | CSTL | $655M | -27.12 | 1.39 | -5.1% | 50.72 |
| Candel Therapeutics, Inc. | CADL | $679M | -17.79 | 13.08 | -73.5% | -17.28 |
| Design Therapeutics, Inc. | DSGN | $672M | -9.63 | 3.16 | -32.8% | -8.33 |
| CorMedix Inc. | CRMD | $670M | 4.13 | 1.65 | 40.0% | 4.01 |
| Zevra Therapeutics, Inc. | ZVRA | $660M |
| - |
| - |
| - |
| - |
| - |
| - |
| 7.93 |
| 4.27 |
| 53.8% |
| 6.70 |
| SI-BONE, Inc. | SIBN | $660M | - | 3.72 | -10.6% | - |
| Aclaris Therapeutics, Inc. | ACRS | $658M | -10.13 | 6.38 | -63.0% | - |
| First Tracks Biotherapeutics, Inc. | TRAX | $635M | -3.88 | 1.62 | -41.8% | -2.95 |
| Prime Medicine, Inc. | PRME | $627M | -3.12 | 5.19 | -166.4% | -3.38 |
| Peer Median | - | -3.88 | 3.99 | -37.3% | -3.17 | |